Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer

Loi, Sherene; Salgado, Roberto; Adams, Sylvia; Pruneri, Giancarlo; Francis, Prudence A; Lacroix-Triki, Magali; Joensuu, Heikki; Dieci, Maria Vittoria; Badve, Sunil; Demaria, Sandra; Gray, Robert; Munzone, Elisabetta; Drubay, Damien; Lemonnier, Jerome; Sotiriou, Christos; Kellokumpu-Lehtinen, Pirkko Liisa; Vingiani, Andrea; Gray, Kathryn; André, Fabrice; Denkert, Carsten; Piccart, Martine; Roblin, Elvire; Michiels, Stefan (2022-01-11)
 
Avaa tiedosto
Lataukset: 



Loi, Sherene
Salgado, Roberto
Adams, Sylvia
Pruneri, Giancarlo
Francis, Prudence A
Lacroix-Triki, Magali
Joensuu, Heikki
Dieci, Maria Vittoria
Badve, Sunil
Demaria, Sandra
Gray, Robert
Munzone, Elisabetta
Drubay, Damien
Lemonnier, Jerome
Sotiriou, Christos
Kellokumpu-Lehtinen, Pirkko Liisa
Vingiani, Andrea
Gray, Kathryn
André, Fabrice
Denkert, Carsten
Piccart, Martine
Roblin, Elvire
Michiels, Stefan
11.01.2022


3
doi:10.1038/s41523-021-00362-1
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-202204294161

Kuvaus

Peer reviewed
Tiivistelmä
The importance of integrating biomarkers into the TNM staging has been emphasized in the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging system. In a pooled analysis of 2148 TNBC-patients in the adjuvant setting, TILs are found to strongly up and downstage traditional pathological-staging in the Pathological and Clinical Prognostic Stage Groups from the AJJC 8th edition Cancer Staging System. This suggest that clinical and research studies on TNBC should take TILs into account in addition to stage, as for example patients with stage II TNBC and high TILs have a better outcome than patients with stage I and low TILs.
Kokoelmat